Patrick Y. Yang Sells 20,000 Shares of Codexis, Inc. (NASDAQ:CDXS) Stock


Share on StockTwits

Codexis, Inc. (NASDAQ:CDXS) Director Patrick Y. Yang sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, April 6th. The stock was sold at an average price of $24.71, for a total value of $494,200.00.

NASDAQ CDXS opened at $23.82 on Thursday. Codexis, Inc. has a 12 month low of $9.91 and a 12 month high of $29.56. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of -68.06 and a beta of 1.17. The company’s 50 day moving average is $22.21 and its two-hundred day moving average is $19.62.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings data on Thursday, February 25th. The biotechnology company reported ($0.06) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.07. The firm had revenue of $21.03 million for the quarter, compared to the consensus estimate of $20.36 million. Codexis had a negative net margin of 31.08% and a negative return on equity of 21.25%. Sell-side analysts predict that Codexis, Inc. will post -0.47 earnings per share for the current fiscal year.

Several equities analysts have recently weighed in on CDXS shares. Benchmark increased their price objective on shares of Codexis from $21.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, December 30th. Zacks Investment Research upgraded shares of Codexis from a “sell” rating to a “hold” rating in a research note on Wednesday, March 3rd. HC Wainwright boosted their price objective on shares of Codexis from $21.00 to $26.00 and gave the company a “buy” rating in a research report on Thursday, March 4th. Finally, Stifel Nicolaus began coverage on Codexis in a report on Monday, March 8th. They issued a “buy” rating and a $30.00 target price on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Codexis has a consensus rating of “Buy” and a consensus price target of $23.20.

Large investors have recently bought and sold shares of the business. Penserra Capital Management LLC purchased a new position in shares of Codexis in the fourth quarter valued at about $30,000. International Assets Investment Management LLC bought a new stake in Codexis during the 4th quarter valued at approximately $57,000. Nisa Investment Advisors LLC raised its stake in Codexis by 18.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,140 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 800 shares during the period. Prelude Capital Management LLC purchased a new position in Codexis in the 4th quarter worth approximately $211,000. Finally, LPL Financial LLC bought a new position in Codexis in the 4th quarter worth approximately $212,000. 91.33% of the stock is currently owned by institutional investors and hedge funds.

About Codexis

Codexis, Inc discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services.

Further Reading: Dead Cat Bounce

Insider Buying and Selling by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.